Friday, September 25, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchkisspeptinbeta-celltype 2 diabetespreclinical

Kisspeptin-13 outperforms other isoforms on beta-cell function in mouse study

KP-14 resisted plasma degradation while KP-13 and KP-10 underwent N-terminal proteolysis, with distinct metabolic effects across the three peptides.

PR
By Priya Raman · Science Reporter
Sep 16 20:00 ETSource: Metabolites

The wire

  1. 01In BRIN-BD11 cells, isolated murine islets and healthy mice, KP-13 was the most efficacious on insulin secretion, enhanced beta-cell proliferation more than exenatide and protected against cytokine-induced apoptosis.
  2. 02All three kisspeptin isoforms suppressed food intake and raised circulating glucose acutely, but KP-13 alone did not impair glucose tolerance, which the authors frame as a possible type 2 diabetes application.
  3. 03Work was confined to cell lines and healthy mice; no diabetic models or human data, and isoform stability differences may not translate to human plasma.

From the source

Enzymatic Stability and Comparative Effects of Kisspeptin-14, Kisspeptin-13 and Kisspeptin-10 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation

Metabolites · 2026 Sep 17 · Spratt JA, Tanday N, McGinn DM et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →